公开(公告)号：US20220062378A1

公开(公告)日：2022-03-03

申请号：US17254734

申请日：2019-06-19

Applicant: UNIVERSITY OF ROCHESTER ,  UNIVERSITY OF COPENHAGEN, A DENMARK UNIVERSITY

Inventor： Steven A. GOLDMAN ,  Mikhail OSIPOVITCH

IPC: A61K38/17 ,  A61K35/30 ,  A61P25/28

Abstract: The disclosure herein relates generally to a method of treating or inhibiting onset of Huntington's disease. This method involves selecting a subject having or at risk of having Huntington's disease and administering to the subject one or modulators of one or more genes as described herein, or proteins encoded therefrom, under conditions effective to treat or inhibit onset of Huntington's disease in the subject.

公开(公告)号：US20210260002A1

公开(公告)日：2021-08-26

申请号：US17254008

申请日：2019-06-18

Applicant: UNIVERSITY OF ROCHESTER ,  UNIVERSITY OF COPENHAGEN

Inventor： Steven A. GOLDMAN ,  Zhengshan LIU ,  Mikhail OSIPOVITCH

IPC: A61K31/19 ,  A61K31/4184 ,  A61K31/5377 ,  C12N15/113 ,  A61P25/28

Abstract: The present disclosure is directed to methods of restoring glial cell K+ uptake in a subject. This method involves selecting a subject having impaired glial cell K+ uptake, and administering, to the selected subject, a RE1-Silencing Transcription factor (REST) inhibitor under conditions effective to restore glial cell K+ uptake. Subjects having impaired glial cell K+ uptake include those at risk of having or having a neuropsychiatric disease or disorder.